Stay updated on PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Sign up to get notified when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.

Latest updates to the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page
- Check3 days agoChange DetectedAdded new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment-status note ('No longer looking for participants'), improving visibility and user flow. The Intervention header was updated from 'Intervention / Treatment' to 'Intervention/Treatment' and the page revision tag updated to v3.6.0, while the old label was removed.SummaryDifference0.4%

- Check11 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing Revision: v3.5.4. This indicates an administrative update to the page's revision history.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedA new publication citation is added to the Publications section, reporting Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in PD-L1-unselected, metastatic NSCLC. The publication record is updated to Revision: v3.5.4, replacing the prior v3.5.3 entry.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page’s displayed revision version was incremented from **v3.5.2** to **v3.5.3**, reflecting a site/version update without altering the study details shown.SummaryDifference0.0%

- Check60 days agoChange DetectedThe Spartalizumab publication citation was updated to Revision: v3.5.2 with an erratum added, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check82 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.0%

Stay in the know with updates to PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.